Loading...
XASX
IBX
Market cap1mUSD
May 02, Last price  
0.01AUD
1D
-7.14%
1Q
-13.33%
IPO
-91.14%
Name

Imagion Biosystems Ltd

Chart & Performance

D1W1MN
P/E
—
P/S
0.98
EPS
—
Div Yield, %
—
Shrs. gr., 5y
37.99%
Rev. gr., 5y
45.35%
Revenues
3m
+94.89%
001220,102191,477410,854205,717232,865473,4291,367,4772,665,135
Net income
-2m
L-83.43%
-2,514,978-4,400,945-1,034,477-7,794,602-8,347,766-5,466,185-7,795,098-8,639,207-9,809,193-12,473,916-2,066,957
CFO
-1m
L-84.72%
-2,430,657-4,223,809-267,256-6,977,385-8,133,975-4,182,045-4,623,090-5,068,491-8,701,010-8,315,963-1,270,611
Earnings
May 29, 2025

Profile

Imagion Biosystems Limited provides medical imaging technologies based on superparamagnetic relaxometry for cancer and disease detection, and monitoring therapy. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company develops MagSense, which is in Phase I clinical trials for the treatment of HER2 breast cancers; and PrecisionMRX, an iron oxide nanoparticle to detect cancer. Imagion Biosystems Limited has a collaborative research program with Patrys Limited to use the combined technologies for enhancing brain tumor imaging and diagnosis; and a joint development agreement with Global Cancer Technology, Inc. to develop GCT's novel nanoscintillator technology for the treatment of breast cancer. The company was incorporated in 2016 and is based in San Diego, California.
URL
https://imagionbiosystems.com/
IPO date
Jun 22, 2017
Employees
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,665
94.89%
1,367
188.85%
473
103.31%
Cost of revenue
3,422
20,785
12,748
Unusual Expense (Income)
NOPBT
(757)
(19,418)
(12,275)
NOPBT Margin
Operating Taxes
(3,534)
2
Tax Rate
NOPAT
(757)
(15,883)
(12,277)
Net income
(2,067)
-83.43%
(12,474)
27.17%
(9,809)
13.54%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,383
3
BB yield
-22.02%
-0.41%
Debt
Debt current
2,847
2,796
1,041
Long-term debt
54
6,831
8,168
Deferred revenue
Other long-term liabilities
4
2
Net debt
231
9,400
4,763
Cash flow
Cash from operating activities
(1,271)
(8,316)
(8,701)
CAPEX
(190)
(507)
Cash from investing activities
84
(190)
(469)
Cash from financing activities
3,610
4,292
(962)
FCF
1,479
(13,150)
(16,918)
Balance
Cash
2,671
227
4,446
Long term investments
Excess cash
2,537
159
4,422
Stockholders' equity
(2,283)
(3,788)
4,677
Invested Capital
2,847
6,042
4,861
ROIC
ROCE
EV
Common stock shares outstanding
44,948
30,483
28,032
Price
0.02
-93.52%
0.36
1,379.17%
0.02
-68.42%
Market cap
1,034
-90.45%
10,822
1,508.55%
673
-66.20%
EV
1,264
20,221
5,435
EBITDA
(364)
(18,234)
(11,167)
EV/EBITDA
Interest
1,128
2
Interest/NOPBT